At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,049 enrolled
Drug / intervention
albiglutide +6 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating albiglutide, sitagliptin, and 5 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 1,049 participants across 386 sites in 11 countries.
Detailed Summary
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAlbania, Germany, Hong Kong, Mexico, Peru, Philippines, Russia, South Africa, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionJan 2012
Study CompletionApr 2013
TodayJul 2026
First PostedFeb 9, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.4 years ago
Interventions
albiglutidebiological
albiglutide
sitagliptindrug
sitagliptin
glimepiridedrug
Glimepiride
metformindrug
Metformin
placebo albiglutidebiological
placebo to match albiglutide
placebo sitagliptindrug
placebo to match sitagliptin
placebo glimepiridedrug
placebo to match glimepiride